Evaluation of drug-targetable genes by defining modes of abnormality in gene expression

Area of Science:

• Genomics and Bioinformatics
• Cancer Biology
• Drug Discovery

Background:

• Identifying disease-associated genes is crucial but challenging for clinical application.
• Assessing the diversity of genetic abnormalities and their potential for therapeutic intervention is necessary.
• Current methods lack established standards for selecting effective drug targets.

Purpose of the Study:

• To demonstrate the utility of simply restorable genes as viable drug targets.
• To introduce and apply a novel concept of "drug targetability" for evaluating gene abnormalities.
• To identify and validate potential drug targets for breast cancer.

Main Methods:

• Developed a computational method to predict "drug targetability" for abnormal genes.
• Applied the method to breast cancer, identifying PTPRF, PRKAR2B, MAP4K3, and RICTOR as highly targetable.
• Validated predictions through siRNA-mediated gene knockdown, cell death, and migration assays.

Main Results:

• Identified four key genes (PTPRF, PRKAR2B, MAP4K3, RICTOR) as highly drug-targetable in breast cancer.
• Experimental validation confirmed the impact of knocking down these genes on cancer cell behavior.
• In silico analysis suggested that inhibiting RICTOR or PTPRF could extend patient lifespan.

Conclusions:

• The developed "drug targetability" concept offers a practical approach for selecting novel drug targets.
• Identified genes like RICTOR and PTPRF show promise as therapeutic targets for breast cancer.
• This method has the potential to significantly improve disease treatment efficacy.